Pancreatic Enzyme Products + Olaparib
Olaparib brand name: Lynparza.
We found no known interaction between Pancreatic Enzyme Products and Olaparib in our sources. Absence of a documented interaction is not the same as proven safety, and does not guarantee one does not exist. Do not start, stop, or change a medication or supplement based on this page; confirm with your pharmacist or doctor first. Additionally, although there is no interaction, the two are separately associated with some of the same side effects, which would make a new symptom harder to attribute to one or the other.
Pancreatic Enzyme Products and Olaparib
We checked these two against our interaction database. Here is what we found.
No Known Interaction Found
We did not find a documented interaction between Olaparib and Pancreatic Enzyme Products in our sources. This does not guarantee that the combination is completely free of risk — there is often limited research on supplements and herbal products, especially around drug interactions.
If you decide to take both, the practical routine is simple: add one new thing at a time and note the date you started it. If the combination is going to disagree with you, it usually shows in the first days to a couple of weeks — and a start date turns “I’ve been feeling off” into something a pharmacist can actually work with. Do not stop a prescribed medicine on your own.
Always talk with your pharmacist or doctor before making changes to your medications or supplements, particularly if you take several medications or have an ongoing health condition.
Pancreatic Enzyme Products safety at a glance
Safety guidance is general; always confirm with your pharmacist or doctor for your situation.
Why No Interaction Is Listed for Olaparib
Interactions in our licensed database are recorded against drug classes, not just single drug names. Olaparib is filed under 2 classifications — cytochrome p450 3a4 (cyp3a4) substrates, oral drugs. Pancreatic Enzyme Products has documented interactions with 1 drug class — the most serious being acarbose (precose, prandase) (moderate) — and none of Olaparib’s classifications are among them.
Classification data comes from our licensed Natural Medicines dataset. A medication can belong to classes beyond those recorded there, so this describes how the check was run — it is not a safety guarantee.
Pancreatic Enzyme Products Does Interact With Other Medications
Pancreatic Enzyme Products has 1 moderate known drug interaction in our database — Olaparib isn’t one of them. If you take anything else, check it against the full list below.
Check Another of Your Medications Against Pancreatic Enzyme Products
We haven’t checked that one against Pancreatic Enzyme Products yet — ask our pharmacists directly.
Covers the 2,830 medications we’ve checked against Pancreatic Enzyme Products. Pick one to open its full report.
What Olaparib Is Prescribed For, and What Pancreatic Enzyme Products Has Been Studied For
These two come up together because they touch the same health topic — not because they do the same job. Olaparib is a prescription medicine with approved uses on its FDA label. Pancreatic Enzyme Products is a supplement: what follows is what researchers have looked at it for, and how strong that evidence is.
Olaparib is prescribed for: Lynparza (olaparib) is used to treat adults with certain ovarian, fallopian tube, or primary peritoneal cancers that carry BRCA or other DNA-repair gene mutations — both as a maintenance therapy after platinum-based chemotherapy (including in combination with bevacizumab for some patients) and for recurrent disease. It is also approved for HER2-negative breast cancer with a germline BRCA mutation, both in early high-risk disease (adjuvant setting) and in metastatic disease. Lynparza is additionally used as maintenance therapy for adults with germline BRCA-mutated metastatic pancreatic adenocarcinoma whose disease has not progressed on first-line platinum-based chemotherapy, and for adults with certain gene-mutated metastatic castration-resistant prostate cancer — either alone (after prior enzalutamide or abiraterone) or in combination with abiraterone and prednisone or prednisolone. All uses require testing for specific genetic mutations using an FDA-approved companion diagnostic before starting treatment.
Pancreatic Enzyme Products has been studied for:
-
Pancreatic cancer studied, not established Pancreatic Enzyme Products has been studied for this. Natural Medicines rates the evidence: Insufficient Reliable Evidence To Rate Read what the research shows
Pancreatic Enzyme Products for pancreatic cancer
It is unclear if oral pancreatic enzyme products improve nutrition status and health in patients with clinically overt exocrine pancreatic insufficiency resulting from pancreatic cancer.
Effectiveness ratings and the research summaries above are the verbatim record from the Natural Medicines database, which grades evidence from “Effective” down to “Insufficient Reliable Evidence To Rate”. A rating below the top of that scale means researchers have looked at it — not that it works, and never that it can stand in for a prescribed medicine. Do not stop or replace Olaparib on your own; if you are taking Pancreatic Enzyme Products for the same health topic, tell your prescriber, especially if the medicine is being adjusted to a target.
See Every Supplement That Interacts With Olaparib
This page covers Pancreatic Enzyme Products only. If you take other supplements — a multivitamin, a sleep aid, something for joints — the Olaparib page lists 138 supplements it has a documented interaction with, worst first, each one explained.
The most serious there right now: Activated Charcoal (major), Grapefruit (major), St. John's Wort (major), Acacia Rigidula (moderate) and Adrafinil (moderate).
By severity: 3 major · 94 moderate · 41 minor.
From our pharmacist’s overview on the Olaparib page
“Grapefruit is the first thing to drop if you take Olaparib (Lynparza). It blocks CYP3A4, the liver enzyme that clears this cancer drug, so levels can climb and side effects with them.”
Reviewed by 2 · Jul 18, 2026
Taking Pancreatic Enzyme Products as Part of a Dietary Supplement Product? Check It for Interactions
We hold 26 real supplement products containing Pancreatic Enzyme Products, each one broken down to its full ingredient list — and combination products often carry several ingredients besides Pancreatic Enzyme Products. Even though Pancreatic Enzyme Products itself has no known interaction with Olaparib, another ingredient on your label might. Find your product and we’ll check every ingredient on its label:
Where Pancreatic Enzyme Products and Olaparib Sit Against Everything Else
Out of every supplement and medication people look up on HelloPharmacist, here is where these two land this week — and which way each has been moving.
#1,272 of 1,452 supplements looked up here in the last 7 days
#1,641 of 2,830 medications looked up here in the last 7 days
Position among everything looked up on this site, not a measure of how commonly either one is used or how important it is. A supplement can climb this list because of a news story. It counts every request to the page, automated ones included, and nothing here identifies anyone.
Where does our data come from?
- Source: the Natural Medicines (TRC Healthcare) clinical database — the evidence-graded professional reference for herb & supplement interactions.
- Citation library: 103,510 references behind our interaction content, 65,311 of them resolved to verified PubMed/DOI sources. See every Pancreatic Enzyme Products reference on this page ↓
- Freshness: we automatically re-check this combination every week — this pair was last verified September 27, 2026. The Pancreatic Enzyme Products and Olaparib records this page draws on were last updated July 10, 2026.
- What “no known interaction” means: no documented interaction in the sources above — not a guarantee of safety. Supplements are studied far less than prescription drugs, so we say exactly what the evidence supports, and nothing more.
About Pancreatic Enzyme Products
What is Pancreatic Enzyme Products?
- Trouble digesting food (exocrine pancreatic insufficiency)
- Cystic fibrosis
- Chronic pancreatitis
- After pancreas surgery or removal
- Pancreatic cancer-related digestion problems
- Bloating and gas (over-the-counter products)
Pancreatic enzyme products supply the digestive enzymes (lipase, protease, and amylase) that some people cannot make enough of, helping them break down and absorb food. Prescription versions are well-proven and FDA-approved for conditions like cystic fibrosis and chronic pancreatitis, while over-the-counter 'pancreatin' supplements are not as tightly regulated. Always work with a doctor or pharmacist to get the right product and dose.
Pancreatic tissue (usually from pigs or cattle) · Capsules, delayed-release (enteric-coated) capsules, tablets, and powders
An interaction check asks whether these two react with each other — it does not ask whether Pancreatic Enzyme Products is a good idea for someone in your situation. Here is what our Pancreatic Enzyme Products record says about it on its own.
Pancreatic Enzyme Products: dosing
There is no single dose that fits everyone. Prescription pancreatic enzymes are dosed based on the amount of lipase units per meal, the person's body weight (especially in children), and how severe the enzyme shortage is. Your doctor will adjust the dose based on your symptoms, weight, and nutrition.In general, these products are taken with meals and snacks, often with the dose split so part is taken at the start of the meal. Enteric-coated capsules should usually be swallowed whole and not crushed or chewed.
From our Pancreatic Enzyme Products monograph — the full record covers uses, side effects and every documented interaction.
About Olaparib
What Is Olaparib Used For?
Brand name: Lynparza
Lynparza (olaparib) is used to treat adults with certain ovarian, fallopian tube, or primary peritoneal cancers that carry BRCA or other DNA-repair gene mutations — both as a maintenance therapy after platinum-based chemotherapy (including in combination with bevacizumab for some patients) and for recurrent disease. It is also approved for HER2-negative breast cancer with a germline BRCA mutation, both in early high-risk disease (adjuvant setting) and in metastatic disease.
Lynparza is additionally used as maintenance therapy for adults with germline BRCA-mutated metastatic pancreatic adenocarcinoma whose disease has not progressed on first-line platinum-based chemotherapy, and for adults with certain gene-mutated metastatic castration-resistant prostate cancer — either alone (after prior enzalutamide or abiraterone) or in combination with abiraterone and prednisone or prednisolone. All uses require testing for specific genetic mutations using an FDA-approved companion diagnostic before starting treatment.
Most-Reported Side Effects for Olaparib
From FAERS, the FDA’s public side-effect reporting system (20,798 reports, all brands). Reports are voluntary and are not proof the drug caused the effect.
Other Drugs & Pancreatic Enzyme Products
Browse every other medication we’ve checked against Pancreatic Enzyme Products — both the ones with a known interaction and the ones without. Select any drug for the full detail.
No drugs match “”.
1 interaction
No interaction 2,828 drugs checked — show the list
We also checked Pancreatic Enzyme Products against these medications and found no known interaction in our sources. Open any page to confirm.
- Apixaban ›
- Amlodipine ›
- Levothyroxine ›
- Methylphenidate ›
- Warfarin ›
- Abemaciclib ›
- Ivermectin ›
- Testosterone ›
- Sertraline ›
- Acetaminophen ›
- Losartan Potassium ›
- Aspirin ›
- Rosuvastatin ›
- Metoprolol ›
- Escitalopram ›
- Clopidogrel ›
- Rivaroxaban ›
- Atorvastatin ›
- Isotretinoin ›
- Methamphetamine ›
- Tirzepatide ›
- Warfarin Sodium ›
- Ibuprofen ›
- Docusate ›
- Amlodipine Besylate ›
- Sumatriptan ›
- Valacyclovir ›
- Hydroxyurea ›
- Tadalafil ›
- Prednisone ›
- Metformin ›
- Semaglutide ›
- Amitriptyline ›
- Lisdexamfetamine ›
- Propranolol ›
- Amphetamine ›
- Methotrexate ›
- Amoxicillin ›
- Lisinopril ›
- Levothyroxine, Liothyronine ›
- Bupropion ›
- Fluoxetine ›
- Bendamustine ›
- Doxycycline ›
- Azithromycin ›
- Pregabalin ›
- Lamotrigine ›
- Gabapentin ›
- Dextroamphetamine ›
- Acyclovir ›
- Naproxen ›
- Quetiapine ›
- Clonazepam ›
- Buspirone ›
- Omeprazole ›
- Duloxetine ›
- Acetaminophen, Aspirin, Caffeine ›
- Letrozole ›
- Acetaminophen, Codeine ›
- Citalopram ›
Showing the 60 most looked-up of 2,828 medications checked with no known interaction — see the full Pancreatic Enzyme Products list.
Pancreatic Enzyme Products References
The 40 references that drive our Pancreatic Enzyme Products monograph and interaction data, from the evidence-graded Natural Medicines (TRC Healthcare) database. Citations with a link open the study on PubMed or the publisher’s site.
- Martindale W. Martindale the Extra Pharmacopoeia. Pharmaceutical Press, 1999.
- McEvoy GK, ed. AHFS Drug Information. Bethesda, MD: American Society of Health-System Pharmacists, 1998.
- Smyth RL, van Velzen D, Smyth AR, et al. Strictures of ascending colon in cystic fibrosis and high-strength pancreatic enzymes. Lancet 1994;343:85-6. PubMed
- Bergner A, Bergner RK. Pulmonary hypersensitivity associated with pancreatin powder exposure. Pediatrics 1975;55:814-7. DOI
- Wiessmann KJ, Baur X. Occupational lung disease following long-term inhalation of pancreatic extracts. Eur J Respir Dis 1985;66:13-20.
- Bragelmann, R., Armbrecht, U., Rosemeyer, D., Schneider, B., Zilly, W., and Stockbrugger, R. W. The effect of pancreatic enzyme supplementation in patients with steatorrhoea after total gastrectomy. Eur.J Gastroenterol.Hepatol. 1999;11(3):231-237. PubMed
- Halm, U., Loser, C., Lohr, M., Katschinski, M., and Mossner, J. A double-blind, randomized, multicentre, crossover study to prove equivalence of pancreatin minimicrospheres versus microspheres in exocrine pancreatic insufficiency. Aliment.Pharmacol.Ther. PubMed
- O'Keefe, S. J., Cariem, A. K., and Levy, M. The exacerbation of pancreatic endocrine dysfunction by potent pancreatic exocrine supplements in patients with chronic pancreatitis. J Clin Gastroenterol. 2001;32(4):319-323. PubMed
- Shin, S. Y., Hur, G. Y., Ye, Y. M., and Park, H. S. A case of occupational rhinitis caused by porcine pancreatic extract developing into occupational asthma. J Korean Med Sci. 2008;23(2):347-349. PubMed
- Andersen, H. O., Hjelt, K., Waever, E., and Overgaard, K. The age-related incidence of meconium ileus equivalent in a cystic fibrosis population: the impact of high-energy intake. J Pediatr Gastroenterol.Nutr 1990;11(3):356-360. DOI
- Ramo, O. J., Puolakkainen, P. A., Seppala, K., and Schroder, T. M. Self-administration of enzyme substitution in the treatment of exocrine pancreatic insufficiency. Scand.J Gastroenterol. 1989;24(6):688-692. PubMed
- Aparisi, L., Rodrigo, J. M., Serra, M. A., Del Olmo, J., Bisquert, M., and Raga, F. [Efficacy of a new microencapsulated pancreatin versus a conventional preparation, in the treatment of steatorrhea of pancreatic origin]. Rev.Esp.Enferm.Apar.Dig. 1989;76
- Ansaldi-Balocco, N., Santini, B., and Sarchi, C. Efficacy of pancreatic enzyme supplementation in children with cystic fibrosis: comparison of two preparations by random crossover study and a retrospective study of the same patients at two different ages DOI
- Beverley, D. W., Kelleher, J., Macdonald, A., Littlewood, J. M., Robinson, T., and Walters, M. P. Comparison of four pancreatic extracts in cystic fibrosis. Arch Dis.Child 1987;62(6):564-568. PubMed
- Silber, W. Pankreoflat in benign diseases of the oesophagus: a blind therapeutic trial. S.Afr.Med J 7-7-1973;47(26):1137-1138.
- Sack, J., Blau, H., Goldfarb, D., Ben-Zaray, S., and Katznelson, D. Hyperuricosuria in cystic fibrosis patients treated with pancreatic enzyme supplements. A study of 16 patients in Israel. Isr.J Med Sci. 1980;16(6):417-419.
- Oades, P. J., Bush, A., Ong, P. S., and Brereton, R. J. High-strength pancreatic enzyme supplements and large-bowel stricture in cystic fibrosis. Lancet 1-8-1994;343(8889):109. DOI
- Mac Sweeney, E. J., Oades, P. J., Buchdahl, R., Rosenthal, M., and Bush, A. Relation of thickening of colon wall to pancreatic-enzyme treatment in cystic fibrosis. Lancet 3-25-1995;345(8952):752-756. PubMed
- Jones, R., Franklin, K., Spicer, R., and Berry, J. Colonic strictures in children with cystic fibrosis on low-strength pancreatic enzymes. Lancet 8-19-1995;346(8973):499. DOI
- Taylor, C. J. and Steiner, G. M. Fibrosing colonopathy in a child on low-dose pancreatin. Lancet 10-21-1995;346(8982):1106-1107. PubMed
- Ong, P. S., Oades, P. J., Bush, A., and Brereton, R. J. Colonic stricture in a boy with cystic fibrosis. Postgrad.Med J 1995;71(835):309-312. PubMed
- Milla, C. E., Wielinski, C. L., and Warwick, W. J. High-strength pancreatic enzymes. Lancet 3-5-1994;343(8897):599. DOI
- McHugh, K., Thomson, A., and Tam, P. Case report: colonic stricture and fibrosis associated with high-strength pancreatic enzymes in a child with cystic fibrosis. Br.J Radiol. 1994;67(801):900-901. PubMed
- Nouisa-Arvanitakis, S., Stapleton, F. B., Linshaw, M. A., and Kennedy, J. Therapeutic approach to pancreatic extract-induced hyperuricosuria in cystic fibrosis. J Pediatr 1977;90(2):302-305. PubMed
- Lancellotti, L., Cabrini, G., Zanolla, L., and Mastella, G. High- versus low-lipase acid-resistant enzyme preparations in cystic fibrosis: a crossover randomized clinical trial. J Pediatr.Gastroenterol.Nutr. 1996;22(1):73-78. DOI
- FitzSimmons, S. C., Burkhart, G. A., Borowitz, D., Grand, R. J., Hammerstrom, T., Durie, P. R., Lloyd-Still, J. D., and Lowenfels, A. B. High-dose pancreatic-enzyme supplements and fibrosing colonopathy in children with cystic fibrosis. N.Engl.J Med 5-1- PubMed
- Stapleton, F. B., Kennedy, J., Nousia-Arvanitakis, S., and Linshaw, M. A. Hyperuricosuria due to high-dose pancreatic extract therapy in cystic fibrosis. N.Engl.J Med 7-29-1976;295(5):246-248. PubMed
- Bruno, M. J., Haverkort, E. B., Tijssen, G. P., Tytgat, G. N., and van Leeuwen, D. J. Placebo controlled trial of enteric coated pancreatin microsphere treatment in patients with unresectable cancer of the pancreatic head region. Gut 1998;42(1):92-96. PubMed
- Miyoshi, H. and Kanzaki, T. Drug eruption (erythema multiforme type) due to a digestive enzyme drug. J Dermatol. 1998;25(1):28-31. PubMed
- Chazalette, J. P. A Double-Blind Placebo-Controlled Trial of a Pancreatic Enzyme Formulation (Panzytrat 25 000) in the Treatment of Impaired Lipid Digestion in Patients with Cystic Fibrosis. Drug Investigation 1993;5(5):274. DOI
- Seiler CM, Izbicki J, Varga-Szabó L, et al. Randomised clinical trial: a 1-week, double-blind, placebo-controlled study of pancreatin 25 000 Ph. Eur. minimicrospheres (Creon 25000 MMS) for pancreatic exocrine insufficiency after pancreatic surgery, with a
- Lee SK, Kim MS, Lee UH. Acute generalized exanthematous pustulosis induced by a digestive enzyme drug, Festal(®). Clin Exp Dermatol. 2018;43(3):321-323.
- Whitcomb DC, Bodhani A, Beckmann K, et al. Efficacy and safety of pancrelipase/pancreatin in patients with exocrine pancreatic insufficiency and a medical history of diabetes mellitus. Pancreas. 2016;45(5):679-86. PubMed
- Ramesh H, Reddy N, Bhatia S, et al. A 51-week, open-label clinical trial in India to assess the efficacy and safety of pancreatin 40000 enteric-coated minimicrospheres in patients with pancreatic exocrine insufficiency due to chronic pancreatitis. Pancre PubMed
- Toskes PP, Secci A, Thieroff-Ekerdt R; ZENPEP Study Group. Efficacy of a novel pancreatic enzyme product, EUR-1008 (Zenpep), in patients with exocrine pancreatic insufficiency due to chronic pancreatitis. Pancreas. 2011;40(3):376-82. PubMed
- Kahl S, Schütte K, Glasbrenner B, et al. The effect of oral pancreatic enzyme supplementation on the course and outcome of acute pancreatitis: a randomized, double-blind parallel-group study. JOP. 2014;15(2):165-74.
- Trapnell BC, Maguiness K, Graff GR, Boyd D, Beckmann K, Caras S. Efficacy and safety of Creon 24,000 in subjects with exocrine pancreatic insufficiency due to cystic fibrosis. J Cyst Fibros. 2009;8(6):370-7. PubMed
- Carroccio A, Guarino A, Zuin G, et al. Efficacy of oral pancreatic enzyme therapy for the treatment of fat malabsorption in HIV-infected patients. Aliment Pharmacol Ther. 2001;15(10):1619-25. PubMed
- Guidance for Industry Exocrine Pancreatic Insufficiency Drug Products - Submitting NDAs. Available at: https://www.fda.gov/ucm/groups/fdagov-public/@fdagov-drugs-gen/documents/document/ucm071651.pdf. Accessed March 29, 2019.
- Amoateng R, Hardman B, Liu C, Austin S. Rare case of pancrelipase therapy-induced neutropaenia. BMJ Case Rep 2021;14(3):e241799. PubMed
Medication overviews come from MedlinePlus (NIH); supplement label data from the NIH Dietary Supplement Label Database. Content is written and reviewed by licensed HelloPharmacist pharmacists — see our data sources and editorial standards.
Taking Pancreatic Enzyme Products and Olaparib Together: Common Questions
Is it safe to take Pancreatic Enzyme Products with Olaparib?
Do Pancreatic Enzyme Products and Olaparib have any of the same side effects?
Are Pancreatic Enzyme Products and Olaparib used for the same thing?
How was the Pancreatic Enzyme Products and Olaparib combination checked?
Does Pancreatic Enzyme Products interact with any other medications?
Does Olaparib interact with any supplements?
Written and reviewed by the HelloPharmacist editorial staff. Our editorial policy
Keep Exploring
Still Have a Question About Olaparib and Pancreatic Enzyme Products?
Our pharmacists answer your medication & supplement questions — free.
This information is for education only and is not a substitute for professional medical advice. Always check with your pharmacist or doctor before starting, stopping, or combining supplements and medications.